Oncology

February 06, 2023

Gastroesophageal reflux disease is a risk factor for what is now the more common type of esophageal cancer, adenocarcinoma. Immunotherapy is coming on strong as a treatment.

December 26, 2022

This year's most-read cancer news included researchers finding a possible liver cancer immunotherapy, cancer patients facing many negative impacts from COVID-19 and more.

December 08, 2022

The researchers have several suggestions for how harm from screening should be reported in screening guidelines.

November 24, 2022

In this final video of a three-part video series, Oncologist and Vice President of Medical Affairs at Quest Diagnostics, Dr. Yuri Fesko, shares a key takeaway from Quest's recent Health Trends Survey. Results reveal how cancer diagnosis numbers are still lagging to pre-pandemic levels of 11%. Fesko adds that bringing cancer screenings to the community can increase diagnosis numbers, leading to care sooner.

November 23, 2022

Dr. Yuri Fesko of Quest Diagnostics says the "pathways approach" helped one health system speed the time between diagnosis and targeted treatment for lung cancer by as much as a month for some patients. This is the second part of a three-part video series.

November 16, 2022

In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.

November 14, 2022

Positive results for Adcetris (brentuximab vedotin) were reported in The New England Journal of Medicine. Further research will include a look at the cost effectiveness of Adcetris.

November 08, 2022

Dana-Farber Cancer Institute tool evaluates the probability of having genetic mutations that confer elevated risk for 18 cancers.

October 31, 2022

Overall survival is considered a more definitive end point. But according to Vinay Prasad, M.D., M.P.H., and colleagues , drugs approved based on progression-free survival and overall response rate were priced higher than those approved based on overall survival.

October 14, 2022

Escalating costs are hitting patients hard. CMS price negotiation and the $2,000 cap on Part D out-of-pocket expenses should benefit many patients with Medicare coverage.